Research projects
Childhood Cancer Immunotherapy Program
New Childhood Brain Cancer Research
37 Years of Dedication
Introducing the Telethon Kids Cancer Centre
Unlocking the key to leukaemia progression in kids
The new sarcoma research team
Meet Finlay
The SJ Elliot Cancer Trial
Latest publications
Tretinoin improves the anti-cancer response to cyclophosphamide, in a model-selective manner
Chemotherapy is included in treatment regimens for many solid cancers, but when administered as a single agent it is rarely curative. The addition of immune checkpoint therapy to standard chemotherapy regimens has improved response rates and increased survival in some cancers. However, most patients do not respond to treatment and immune checkpoint therapy can cause severe side effects. Therefore, there is a need for alternative immunomodulatory drugs that enhance chemotherapy.
Children's Cancers Published research Subsite: Cancer Sarcoma Translational ResearchFDA-approved disulfiram as a novel treatment for aggressive leukemia
Acute leukemia continues to be a major cause of death from disease worldwide and current chemotherapeutic agents are associated with significant morbidity in survivors. While better and safer treatments for acute leukemia are urgently needed, standard drug development pipelines are lengthy and drug repurposing therefore provides a promising approach.
Children's Cancers Published research Leukaemia Translational ResearchHistological predictors of outcome for cutaneous squamous cell carcinoma in renal transplant patients: A case-control study
Cutaneous squamous cell carcinoma is a significant cause of morbidity for immunosuppressed patients such as organ transplant recipients; however, histological parameters which predict the likelihood of tumor progression are typically based on general population studies in which immunosuppressed patients represent only a small fraction of cases.
Children's Cancers Published research Nutrition in Early LifeHigh-dose chemotherapy for Ewing sarcoma and Rhabdomyosarcoma: A systematic review by the Australia and New Zealand sarcoma association clinical practice guidelines working party
Patients with high-risk or metastatic Ewing sarcoma (ES) and rhabdomyosarcoma (RMS) have a guarded prognosis. High-dose chemotherapy (HDT) with autologous stem cell transplant (ASCT) has been evaluated as a treatment option to improve outcomes. However, survival benefits remain unclear, and treatment is associated with severe toxicities.
Children's Cancers Published research